We showed that trastuzumab–TFBG combination therapy significantly delayed tumor growth and induced dramatic tumor regression by blocking activation of SHCBP1–PLK1–MISP signaling, demonstrating that TFBG is a promising sensitizing agent for combination with trastuzumab to battle HER2-positive gastric cancer. Here, ERBB2 is linked to neoplasm.